Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO): Actionable Protocol Guidance

What This Product Solves

During protein extraction and sample preparation, endogenous proteases may rapidly degrade target proteins, compromising assay results. The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) provides broad-spectrum inhibition against serine, cysteine, aspartic proteases, and aminopeptidases via a mixture of AEBSF, Bestatin, E-64, Leupeptin, and Pepstatin A. Because it is EDTA-free and supplied in DMSO as a 100X concentrate, the cocktail preserves divalent cation-dependent protein interactions and enzymatic activities, making it suitable for workflows such as phosphorylation analysis, Western blotting, co-immunoprecipitation, and kinase assays. This addresses a common need for a protein extraction protease inhibitor that does not disrupt metal ion-dependent processes.

For further protocol comparisons, see the internal article "Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO): Practical Use Cases", which summarizes reproducibility improvements in plant and mammalian systems. Additionally, "Reliable Protein Preservation with Protease Inhibitor Cocktail" discusses integration in Western blotting and phosphorylation workflows.

Protocol Parameters

• General protein extraction | 1:100 (v/v) dilution | All protein lysates, including mammalian and plant | Ensures effective inhibition of multiple protease classes while maintaining compatibility with common lysis buffers | product dossier
• Western blot sample prep | Add cocktail immediately post-lysis, 1:100 (v/v) | For preservation of target proteins during sample handling | Minimizes proteolytic cleavage prior to SDS-PAGE; ensures protein integrity for detection | product dossier
• Phosphorylation or kinase assays | Use EDTA-free buffer and 1:100 (v/v) cocktail | Cation-sensitive workflows (e.g., phosphorylation analysis) | Prevents interference with divalent cation-dependent enzymes or protein complexes | product dossier
• Storage | -20°C, stable for ≥12 months | Stock solution longevity | Maintains inhibitor potency and prevents degradation | product dossier
• Co-immunoprecipitation | 1:100 (v/v) in lysis and wash buffers | Protects protein complexes during enrichment | Prevents proteolysis without disrupting protein-protein interactions or cation-sensitive binding | product dossier
• Immunohistochemistry/Immunofluorescence | Add to permeabilization/fixation buffer if required, 1:100 (v/v) | Use in preservation of antigenicity | Avoids proteolytic loss of epitopes during tissue/sample processing | workflow recommendation

Workflow Setup and QC Checklist

• Buffer Selection: Use EDTA-free lysis buffers for phosphorylation or kinase assays to avoid chelation of essential divalent cations. Ensure that the buffer is compatible with DMSO at the working concentration.
• Cocktail Addition: Add the Protease Inhibitor Cocktail immediately after cell lysis to minimize any window of protease activity. For tissue homogenates or slow lysing systems, pre-addition may be warranted.
• Mixing: After addition, mix samples thoroughly to ensure even distribution. Incomplete mixing can lead to localized proteolysis.
• Temperature Control: Keep all steps on ice or at 4°C post-lysis to further reduce protease activity, in addition to inhibitor use.
• Sample Storage: If samples are not processed immediately, aliquot and freeze at -80°C. Avoid repeated freeze-thaw cycles, which can reactivate proteases or dilute inhibitor potency.
• QC Assay: For Western blot protease inhibitor validation, check for unexpected protein degradation bands; successful inhibition should yield intact target bands at expected molecular weights.

Common Failure Modes and Fixes

• Proteolysis Despite Inhibitor Use: Confirm prompt addition of cocktail post-lysis and validate that the working dilution is correct. Increase inhibitor concentration (up to 2:100 v/v, if protocol allows) for highly protease-rich samples.
• Loss of Phosphorylation Signals: Verify that no EDTA or other chelators are present in the buffer. The EDTA-free formulation is designed to prevent this, but contamination from other reagents can occur.
• Inhibitor Precipitation: If precipitation is observed upon addition, ensure that lysis buffer and sample are at compatible temperatures and that DMSO tolerance is not exceeded; dilute stock if necessary.
• Unexpected Immunoreactivity Loss: For immunoassays, confirm that inhibitors do not interfere with antibody binding by performing a small-scale pilot assay with and without cocktail.

Scope and Limitations

• Scope: The Protease Inhibitor Cocktail EDTA-Free is broadly suitable for workflows requiring preservation of protein integrity in the absence of chelators, such as phosphorylation analysis, kinase assays, Western blotting, co-immunoprecipitation, pull-down assays, immunofluorescence, and immunohistochemistry. It is suitable for both mammalian and plant systems where divalent cation compatibility is required.
• Limitations: This product does not inhibit metalloproteases reliant on chelation, as it is EDTA-free. If metalloprotease inhibition is required, an alternative or supplementary inhibitor may be necessary. The DMSO-based concentrate should not be used in workflows where DMSO is incompatible.
• Boundaries: It is not intended for workflows where removal of divalent cations is critical to the assay, nor should it be used as a substitute for EDTA-containing cocktails in those contexts.

Conclusion

The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) offers a practical, ready-to-use solution for protecting protein integrity in cation-sensitive protein extraction and assay workflows. By avoiding EDTA, it maintains activity of kinases and other cation-dependent enzymes, making it especially relevant for phosphorylation studies and Western blotting where divalent cation preservation is essential. For detailed product specifications and ordering, see APExBIO's product page. Researchers should ensure appropriate integration into their protocols, confirm compatibility with downstream applications, and routinely validate inhibitor performance to safeguard assay integrity.